ClinicalTrials.gg
RecruitingNCT04796844MANIUpdated Nov 28, 2023

MANI Real-life Perspective Observatory

An observational study in Asthma, Mild Asthma and Moderate Asthma, sponsored by Societa Italiana di Pneumologia. Recruiting at 1 site in Italy. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2023-11-28.

Sponsored by Societa Italiana di Pneumologia · Observational

How we know

From the registry’s dates

  • Started May 2021; still recruiting 5 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
20,000
Ages
18 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 177 studies in Asthma with a site in Italy — 20 open to participants now, 29 under way, 10 of them phase 3. Asthma · Italy.

Planned enrollment
Largest of 47
20,000 · median 152
Started
2021
with 14 others
Observational
47 of 177
6 open now
Primary completion
2021-05
later than 0 of 28 live
Registered
119th of 177
by date

Among the 177 studies in Asthma with a site in Italy, this one has the largest planned enrollment of the 47 observational ones that give a count, is one of 15 that started in 2021, is one of 47 observational ones, reaches primary completion later than 0 of the 28 other live ones, and was the 119th registered.

Asthma

4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.

Browse Asthma studies →

Open to participants now

20 of the 177 studies in Asthma with a site in Italy are open now. Recruiting first, the newest first:

14 more — sign in →

All 20 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 416 Asthma studies recruiting now, 141 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 146 take children under 18; 105 take healthy volunteers.

This study: 18 Years to 99 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 177 studies in Asthma with a site in Italy, or all of them as a file.
02

Study summary

The purpose of this registry aims is to collect a large number of patients with mild and moderate asthma in a real-word conditions for a perspective observation of epidemiological evolution of the disease in relation to the therapeutic interventions available currently and in the near future.

Read the detailed description

To represent real-world mild moderate Italian asthmatics, all adults with diagnosed asthma by specialist, according GINA (Global Initiative for Asthma) document, attending respiratory or allergy clinic for a scheduled visit are eligible for study enrollment. If inclusion/exclusion criteria are satisfied, a written consent to participate in the study will be obtained and an informative leaflet for the patient and his/her general practitioners will be delivered.

Subjects follow up will be scheduled according with GINA document and center plan (6 or 12 months follow up visit).

03

Conditions studied

  • Asthma
  • Mild Asthma
  • Moderate Asthma

Browse trials for

Keywords

  • Asthma
  • Adult
  • Cluster
  • Cohort study
  • Italy
  • Prospective
04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

To represent real-world mild moderate Italian asthmatics, all adults with diagnosed asthma by specialist, according GINA document, attending respiratory or allergy clinic for a scheduled visit are eligible for study enrollment. If inclusion/exclusion criteria are satisfied, a written consent to participate in the study will be obtained and an informative leaflet for the patient and his/her GPs will be delivered.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patients
  • Asthma diagnosis according GINA 2020 algorithm (Annex 1)
  • Patients enrolled in other previous or ongoing observational studies

Exclusion criteria

Exclusion Criteria:

  • Severe asthma patients according International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. [Chung KF et al. European Respiratory Journal Feb 2014, 43 (2) 343-373; DOI: 10.1183/09031936.00202013 (Annex 2)]
  • Subjects are excluded from this cohort if they exhibit interstitial lung diseases, pulmonary neoplasms, current lung infections, immunological disorders leading to the use of or continuous treatment with oral .
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
20,000 participants (estimated)
Target follow-up
10 Years
Patient registry
Yes
Biospecimen retention
Samples with dna
06

What researchers measure

Primary outcomes

  1. A cluster-based, real world, cross-sectional perspective, observational cohort study

    Perspective observation of epidemiological evolution of mild and moderate asthma (rate of asthmatic patients transitioned to a more severe stage according Global Initiative for Asthma \[GINA\] document)

    Time frame: through study completion; follow-up procedures will last 10 years from the date of the last patient enrolled

Secondary outcomes

  1. Real life assessment of control, exacerbation and PROs in patients treated with different drugs and schedule

    Real-life assessment of asthma control over time (Asthma Control Test and Asthma Control Questionnaire scores), exacerbation rate over time (n/year) and patient-reported outcomes (e.g., quality of life, patient engagement, disease awareness) from groups treated with different drugs and schedules (questionnaire score)

    Time frame: through study completion; follow-up procedures will last 10 years from the date of the last patient enrolled

  2. Asthma control in pregnant women

    Asthma control in pregnant women by means of a specific application for android- and iOS-based smartphones, in comparison with the traditional current management

    Time frame: through study completion; follow-up procedures will last 10 years from the date of the last patient enrolled

  3. Burden of OCS in mild and moderate asthma

    Burden of oral corticosteroids in mild and moderate asthma (mg/year)

    Time frame: through study completion; follow-up procedures will last 10 years from the date of the last patient enrolled

  4. SABA use in mild and moderate asthma

    SABA use in mild and moderate asthma (canisters/year)

    Time frame: through study completion; follow-up procedures will last 10 years from the date of the last patient enrolled

  5. Influence of infections and vaccinations on disease outcomes and progression

    Influence of infections and vaccinations on disease outcomes and progression (rate of progression; questionnaire score)

    Time frame: through study completion; follow-up procedures will last 10 years from the date of the last patient enrolled

  6. Influence of upper airway disease on disease outcomes and progression

    Influence of upper airway disease on disease outcomes and progression (rate of progression; questionnaire score)

    Time frame: through study completion; follow-up procedures will last 10 years from the date of the last patient enrolled

  7. Impact of inhalation techniques and smart inhalers on disease outcomes and progression

    Impact of inhalation techniques and smart inhalers on disease outcomes and progression (inhalation error/asthma control score; inhalation error/rate of progression)

    Time frame: through study completion; follow-up procedures will last 10 years from the date of the last patient enrolled

  8. Environmental exposure influences on disease outcome and progression

    Environmental exposure influences on disease outcome and progression (PM10/rate of progression)

    Time frame: through study completion; follow-up procedures will last 10 years from the date of the last patient enrolled

  9. Evolution of inflammatory patterns over time

    Evolution of inflammatory patterns over time and their relationships to disease outcomes and progression (published biomarker value/asthma control; published biomarker value/rate of progression)

    Time frame: through study completion; follow-up procedures will last 10 years from the date of the last patient enrolled

  10. Role of smoking and life style in lung function and disease progression

    Role of smoking and life style in lung function and disease progression (pack year/disease progression)

    Time frame: through study completion; follow-up procedures will last 10 years from the date of the last patient enrolled

  11. Patients reported outcomes over time

    Patients reported outcomes over time (score according validated questionnaires)

    Time frame: through study completion; follow-up procedures will last 10 years from the date of the last patient enrolled

  12. Patient awareness and engagement in mild and moderate asthma

    Patient awareness and engagement in mild and moderate asthma (questionnaire score)

    Time frame: through study completion; follow-up procedures will last 10 years from the date of the last patient enrolled

  13. Impact of digital therapy on disease management and outcomes

    Impact of digital therapy on disease management and outcomes (canister/year and dose/year)

    Time frame: through study completion; follow-up procedures will last 10 years from the date of the last patient enrolled

  14. Direct, indirect, and intangible costs of mild and moderate asthma

    Direct, indirect, and intangible costs of mild and moderate asthma (EU/disease severity)

    Time frame: through study completion; follow-up procedures will last 10 years from the date of the last patient enrolled

  15. Cost-efficiency of mild/moderate asthma treatments and management plans

    Cost-efficiency of mild/moderate asthma treatments and management plans (cost/year)

    Time frame: through study completion; follow-up procedures will last 10 years from the date of the last patient enrolled

  16. Sociodemographic issues related to disease progression and burden

    Sociodemographic issues related to disease progression and burden (age, sex, education, employment/rate of progression)

    Time frame: through study completion; follow-up procedures will last 10 years from the date of the last patient enrolled

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Chung KF, Wenzel SE, Brozek JL, Bush A, Castro M, Sterk PJ, Adcock IM, Bateman ED, Bel EH, Bleecker ER, Boulet LP, Brightling C, Chanez P, Dahlen SE, Djukanovic R, Frey U, Gaga M, Gibson P, Hamid Q, Jajour NN, Mauad T, Sorkness RL, Teague WG. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J. 2014 Feb;43(2):343-73. doi: 10.1183/09031936.00202013. Epub 2013 Dec 12. Erratum In: Eur Respir J. 2014 Apr;43(4):1216. Dosage error in article text. Eur Respir J. 2018 Jul 27;52(1):1352020. doi: 10.1183/13993003.52020-2013. Eur Respir J. 2022 Jun 9;59(6):1362020. doi: 10.1183/13993003.62020-2013. PubMed 24337046 ↗
  • Braido F, Blasi F, Canonica GW, Paggiaro P, Beghe B, Bonini M, Carpagnano GE, Del Giacco S, Lavorini F, Milanese M, Patella V, Santus P, Contoli M; MANI Network; Allegrini C, Baiardini I, Bonzano L, Caiaffa MF, Castelnuovo P, Corsico AG, Cosmi L, Costantino MT, Cottini M, Crimi N, Crivellaro MA, D'Alo S, Folletti I, Fornari D, Foschino-Barbaro MP, Franceschini L, Gargano D, Oliani KL, Maniscalco M, Melissari L, Montagni M, Montuschi P, Murgia N, Pannofino A, Papi A, Parente R, Pelaia G, Pini L, Puggioni F, Pulera N, Resta O, Ricciardi L, Ridolo E, Savi E, Savoia F, Scala G, Senna G, Tripodi S, Vatrella A, Ventura MT, Viviano VM, Yacoub MR. Mild/Moderate Asthma Network in Italy (MANI): a long-term observational study. J Asthma. 2022 Sep;59(9):1908-1913. doi: 10.1080/02770903.2021.1968895. Epub 2021 Sep 1. PubMed 34469268 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2021 to primary completion in May 2021, 0 months.

Of 366 non-industry observational studies under Asthma, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 97. This study's 0 months is below that.

Counting every sponsor, half of 456 studies reached it within 36 months; a quarter within 18 and three quarters within 82.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 23, 2021
First posted
Mar 15, 2021
StartActual
May 1, 2021
Primary completionActual
May 1, 2021
CompletionEst.
Nov 2032
Last update
Nov 28, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 28, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04796844
Lead sponsor
Societa Italiana di Pneumologia
Collaborators
Società Italiana di Allergologia, Asma e Immunologia Clinica
Responsible party
Sponsor
First posted
Mar 15, 2021
Start date
May 1, 2021
Primary completion
May 1, 2021
Completion
Nov 2032 (estimated)
Last update
Nov 28, 2023

Study contacts

Fulvio Braido
Contact
fulvio.braido@unige.it
+ 393386036913
Fulvio Braido
principal investigator · IRCCS Ospedale Policlinico San Martino, Department of Internal Medicine (DiMI), University of Genoa

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion